At the same time, future research should explore the combination of NAT10/HK2 inhibitors with existing therapies (immunotherapy, chemotherapy, targeted therapy, etc.)to improve treatment efficacy and develop biomarkers for personalized medical methods of GC. This evidence concerns the gene HK2 and gastric cancer.